|
Daily Medical Update
Rosacea
Saturday, July 11, 2026
|
🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the
last 12 months.
|
Actas dermo-sifiliograficas (2025) - Meta-Analysis, Systematic Review
Key Findings
- Ivermectin improved Investigator Global Assessment and Clinician's Erythema Assessment outcomes more than azelaic acid and metronidazole across the included trials.
- Azelaic acid outperformed metronidazole, while brimonidine and oxymetazoline significantly reduced facial redness.
📋 Practice Implication: Topical treatment selection can reasonably prioritize ivermectin when efficacy is the main goal, while brimonidine or oxymetazoline remain useful for erythema-predominant presentations.
|
Journal of cosmetic dermatology (2026) - Meta-Analysis, Systematic Review
Key Findings
- The pooled clinical response rate was 89.9% (95% CI: 74.4%-99.4%) across 57 patients with refractory rosacea.
- 67.8% achieved an IGA score of 1 or less, 74.6% achieved a CEA reduction of at least 2 points, and DLQI improved from 17.30 to 10.00.
📋 Practice Implication: Reserve oral JAK inhibitors for carefully selected refractory cases or clinical trials, because the response signal is promising but still based on small largely uncontrolled datasets.
|
Journal of cosmetic dermatology (2026) - Randomized Controlled Trial
Key Findings
- By week 8, the oat and aloe moisturizer reduced erythema 50% vs 22% and inflammatory lesion counts 74% vs 6% compared with metronidazole.
- At week 12, erythema reduction remained greater at 54% vs 23% and lesion-count reduction remained greater at 74% vs 17%, with no tolerability issues noted.
📋 Practice Implication: Barrier-supportive anti-inflammatory moisturizers may merit consideration as active treatment adjuncts or alternatives in mild-to-moderate rosacea when metronidazole response is inadequate.
|
The Journal of dermatological treatment (2026) - Randomized Controlled Trial
Key Findings
- At week 16, KTP laser plus topical ivermectin produced a larger Normalized Erythema Index reduction than laser alone (16.6% vs 5.3%; p = 0.04).
- Adjunctive ivermectin also improved papule reduction across visits (p = 0.02), with no serious adverse events reported.
📋 Practice Implication: For patients pursuing vascular laser treatment, adding topical ivermectin may modestly improve erythema and inflammatory lesion control without sacrificing tolerability.
|
The Journal of dermatological treatment (2025) - Randomized Controlled Trial
Key Findings
- At week 12, tranilast plus minocycline achieved a 93.33% IGA success rate vs 53.33% with tranilast and 46.67% with minocycline alone.
- CEA success rate, erythema index, and erythema score all improved more with combination therapy than with minocycline (p = 0.021, 0.030, and 0.024).
📋 Practice Implication: In moderate-to-severe rosacea, tranilast plus minocycline appears more effective than either agent alone and may be a reasonable escalation strategy where tranilast is available.
|
|
💡
Summary
Recent rosacea evidence is dominated by treatment studies, with the strongest signals favoring ivermectin-containing regimens, combination therapy for moderate-to-severe disease, and a randomized trial in which an oat and aloe anti-inflammatory moisturizer outperformed topical metronidazole. A small meta-analysis also suggests oral JAK inhibitors may help refractory rosacea, but that signal remains preliminary and should not displace established therapies without confirmatory randomized trials.
|
|